Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 4,117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Pancreatic Cancer
Interventions: N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome; Biological · Drug · Procedure
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: El Segundo, California • Newport Beach, California • East Brunswick, New Jersey + 1 more

Conditions: First Trimester Abortion, Virtual Reality
Interventions: applied VR headset; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Volunteers.
Interventions: AZD6423, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Premature Birth
Interventions: Betamethasone - ACTIVE, Normal Saline - PLACEBO; Drug · Other
Lead sponsor: Pediatrix; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 6 more

Conditions: Anxiety, Stress
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adverse Drug Events
Interventions: ADE alert assistant; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Non-Small Cell Lung Cancer
Interventions: Ceritinib, Pemetrexed, Docetaxel; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 13
States / cities: Fayetteville, Arkansas • Hollywood, Florida • Jacksonville, Florida + 10 more

Conditions: External Genital Warts
Interventions: Investigational Treatment, Aldara; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Arlington Heights, Illinois

Conditions: Female Sexual Arousal Disorder
Interventions: Caffeine, Placebo; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Prosthetic Joint Infection
Interventions: vancomycin hydrochloride and tobramycin sulfate; Combination Product
Lead sponsor: Osteal Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Saginaw, Michigan • Charlotte, North Carolina • Oklahoma City, Oklahoma + 1 more

Conditions: Ketones, Metabolism
Interventions: SGLT2 inhibitor, Controlled, Adaptive Study Diet; Drug · Other
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
Interventions: IDOV-Immune (oncolytic vaccinia virus); Biological
Lead sponsor: ViroMissile, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: St Louis, Missouri • Houston, Texas • San Antonio, Texas

Conditions: Metastatic Breast Cancer, Advanced Breast Cancer
Interventions: ertumaxomab; Drug
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Lebanon, New Hampshire • New York, New York

Conditions: Dietary Intervention, Dietary Proteins, Dietary Assessment, Cognitive Ability, General
Interventions: Ready-to-eat beef in frozen, 5-oz packages, Ready-to-eat beef in frozen, 1-oz packages; Dietary Supplement
Lead sponsor: University of Nebraska Lincoln; Other
Eligibility: 19 Years to 24 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Obesity
Interventions: No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.; Other
Lead sponsor: Oklahoma State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Timeline: 2022
U.S. locations: 1
States / cities: Stillwater, Oklahoma

Conditions: Fragile X Syndrome
Interventions: Baclofen, Memantine, Roflumilast, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Long COVID, PASC Post Acute Sequelae of COVID 19
Interventions: Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo; Drug
Lead sponsor: Bateman Horne Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acne Vulgaris
Interventions: FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam; Combination Product · Drug · Other
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 35
States / cities: Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more

Conditions: Thoracoabdominal Aneurysms
Interventions: Visceral Manifold and Thoracic Bifurcation, Unitary Manifold; Device
Lead sponsor: Sanford Health; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Acne Vulgaris, Acne
Interventions: CT Gel, Clindamycin Gel (clindamycin ), Tretinoin Gel (tretinoin), Vehicle Gel; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years and older
Enrollment: 1,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 27
States / cities: Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 24 more

Conditions: Alzheimer's Disease
Interventions: Dimebon, Placebo comparator; Drug
Lead sponsor: Medivation, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 52
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more

Conditions: Occupational Therapy Students
Interventions: Mindful Self Care Survey (MSCS), Placebo; Behavioral · Other
Lead sponsor: Lauren Newhouse; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Carson, California

Conditions: Food-drug Interaction
Interventions: Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg; Dietary Supplement · Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Virtual Reality Experience in First Trimester D&C

AZD6423 SAD/MAD Study in Healthy Volunteers

Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

Evaluation of Radiology Resident Anxiety When Beginning Emergency Room (ER) Call

Implementation of Real-time ADE Surveillance and Decision Support

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Examining Caffeine as a Treatment for Antidepressant-induced Arousal Dysfunction in Women

Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation

Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers

IDOV-Immune for Advanced Solid Tumors

Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy

Investigating the Effects of Beef Consumption on Cognitive and Brain Health

Gut Permeability-related Inflammation and Cardiovascular Disease Risk in Normal-weight and Metabolically Healthy Obesity

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Visceral Manifold and Unitary Device Study for the Repair of Thoracoabdominal Aortic Aneurysms

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

Enhancing Occupational Therapy Graduate Student Well-Being

Licorice Botanical Dietary Supplements - Metabolism and Safety in Women